Evaluation of Erythroferrone as a New Biomarker of Erythropoesis Stimulating Agents
Status:
Unknown status
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
The main objective of this research is to demonstrate the possible use of erythroferrone
(ERFE) as a potential marker of recombinant human erythropoietin (rHuEpo) use to be included
in the Athlete Biological Passport (PBA) developed by the World Anti-Doping Agency (WADA).
Phase:
Phase 1
Details
Lead Sponsor:
Association Athletes For Transparency
Collaborators:
Centre d'Investigation Clinique Lyon (CIC) Ecole Nationale de Ski et d'Alpinisme (ENSA) Partnership for Clean Competition University of Milan School of Medicine